Myriam Soto-Gordoa
Myriam Soto-Gordoa has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Arantzazu Arrospide
AP-OSI Research Unit, Alto Deba Integrated Health Care Organization, Mondragon, Spain
15 shared publications Javier Mar
Health Services Research on Chronic Patients Network (REDISSEC), Kronikgune Group, Barakaldo, Spain
8 shared publications- Javier Mar
Biogipuzkoa Health Research Institute, Donostia-San Sebastián, Spain
7 shared publications - Juan Ignacio Igartua
Mondragón University
3 shared publications Ane Fullaondo
Kronikgune, Barakaldo, Spain
2 shared publicationsEsteban de Manuel
Kronikgune, Barakaldo, Spain
2 shared publications
Latest Publications
- 30 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (2) , 900-911
Economic model of Alzheimer's disease that incorporates the uncertainty associated with measuring efficacy in clinical trials
Background: Clinical trials of Alzheimer's disease (AD) treatments are ongoing, and uncertainty about their efficacy is a key factor in their evaluation. Objective: The objective of this study was to propose a new methodological approach for the economic evaluation of treatments to account for the uncertainty associated with measuring efficacy in clinical trials and the waning effect. Methods: A discrete event simulation model was built using data from a synthetic clinical trial dataset to model typical patient-level natural history trajectories of Clinical Dementia Rating scores from mild cognitive impairment to severe dementia using mixed regression models for repeated measures (MMRM). As the MMRM coefficients are correlated, this variability was incorporated into the model probabilistic sensitivity analysis using Cholesky decomposition. Uncertainty about treatment effect waning was addressed by scenario analysis (optimistic and pessimistic). Results: Although the main contribution of this study is to describe an innovative model, the results of the hypothetical intervention are presented in the standard format of incremental cost-utility ratios (ICURs), cost-effectiveness and acceptability curves. Specifically, the ICUR of the hypothetical treatment ranged from €73,216 to €63,662 per quality-adjusted life year. Conclusions: We present an innovative approach to the economic evaluation of Alzheimer's disease treatments, applying a Monte Carlo simulation approach (PSA) to two scenarios and shaping individual cognitive trajectories on a continuous scale to fit the target population of clinical trials. Its transparent design allows the economic model to be shared between the pharmaceutical company and the assessment agencies while keeping individuals’ clinical trial data confidential.
- 30 September 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 114 (2) , 900-911
Economic model of Alzheimer's disease that incorporates the uncertainty associated with measuring efficacy in clinical trials
Background: Clinical trials of Alzheimer's disease (AD) treatments are ongoing, and uncertainty about their efficacy is a key factor in their evaluation. Objective: The objective of this study was to propose a new methodological approach for the economic evaluation of treatments to account for the uncertainty associated with measuring efficacy in clinical trials and the waning effect. Methods: A discrete event simulation model was built using data from a synthetic clinical trial dataset to model typical patient-level natural history trajectories of Clinical Dementia Rating scores from mild cognitive impairment to severe dementia using mixed regression models for repeated measures (MMRM). As the MMRM coefficients are correlated, this variability was incorporated into the model probabilistic sensitivity analysis using Cholesky decomposition. Uncertainty about treatment effect waning was addressed by scenario analysis (optimistic and pessimistic). Results: Although the main contribution of this study is to describe an innovative model, the results of the hypothetical intervention are presented in the standard format of incremental cost-utility ratios (ICURs), cost-effectiveness and acceptability curves. Specifically, the ICUR of the hypothetical treatment ranged from €73,216 to €63,662 per quality-adjusted life year. Conclusions: We present an innovative approach to the economic evaluation of Alzheimer's disease treatments, applying a Monte Carlo simulation approach (PSA) to two scenarios and shaping individual cognitive trajectories on a continuous scale to fit the target population of clinical trials. Its transparent design allows the economic model to be shared between the pharmaceutical company and the assessment agencies while keeping individuals’ clinical trial data confidential.
- Open Access
- 8 July 2026
- Published by CERN in Open Research Europe
Predicting health decline in older persons using AI on data from smartwatches: A study protocol of the PAI project.
Background The global shift towards an ageing population and workforce shortages increases demands on health and social care systems. Proactive, personalized, and resource-efficient care models are therefore needed. Continuous monitoring using wearables, together with artificial intelligence (AI), offers potential for early detection of health deterioration and timely intervention. Still, existing solutions often target single diseases and lack integration into clinical workflows. Objective This article presents the study protocol for the project Predicting Care Needs of Older Adults in the Healthcare System through AI-Enabled Analysis of Patient Monitoring Data (PAI), which aims to develop an AI-driven predictive model based on data from wearables (smartwatches) to identify health decline among older persons in the near future. In addition, the project will evaluate the pilot implementation of this model within health and social care settings in three countries and generate recommendations for future adoption. Methods To answer the project aim, the AI model will be developed using historical datasets from wearables linked to emergency health care visits. To guide and evaluate the pilot implementation in Sweden, Norway, and Spain, staff from health and social care, managers, and IT professionals will be interviewed before implementation to explore current work practices and relevant contextual factors. Users of the smartwatch (older persons) will also be interviewed to explore their experiences, needs, and expectations. Follow-up interviews will be conducted after implementation to capture users’ and health and social care staff’s experiences of use. In addition, quantitative data on the AI model’s performance will be collected. The recommendations will be developed in an iterative process, including both researchers and stakeholders. Expected Results The project will identify key data requirements, deliver a predictive AI model, and develop evidence-based recommendations to support the responsible and scalable implementation of the proposed AI-solution in healthcare and social care settings. Conclusions By combining technical innovation with real-world implementation research, the PAI project seeks to advance the use of AI in care for older persons, support proactive and person-centered interventions, and contribute to more sustainable healthcare systems.
- 8 July 2026
- Published by CERN in Open Research Europe
Open AccessPredicting health decline in older persons using AI on data from smartwatches: A study protocol of the PAI project.
Background The global shift towards an ageing population and workforce shortages increases demands on health and social care systems. Proactive, personalized, and resource-efficient care models are therefore needed. Continuous monitoring using wearables, together with artificial intelligence (AI), offers potential for early detection of health deterioration and timely intervention. Still, existing solutions often target single diseases and lack integration into clinical workflows. Objective This article presents the study protocol for the project Predicting Care Needs of Older Adults in the Healthcare System through AI-Enabled Analysis of Patient Monitoring Data (PAI), which aims to develop an AI-driven predictive model based on data from wearables (smartwatches) to identify health decline among older persons in the near future. In addition, the project will evaluate the pilot implementation of this model within health and social care settings in three countries and generate recommendations for future adoption. Methods To answer the project aim, the AI model will be developed using historical datasets from wearables linked to emergency health care visits. To guide and evaluate the pilot implementation in Sweden, Norway, and Spain, staff from health and social care, managers, and IT professionals will be interviewed before implementation to explore current work practices and relevant contextual factors. Users of the smartwatch (older persons) will also be interviewed to explore their experiences, needs, and expectations. Follow-up interviews will be conducted after implementation to capture users’ and health and social care staff’s experiences of use. In addition, quantitative data on the AI model’s performance will be collected. The recommendations will be developed in an iterative process, including both researchers and stakeholders. Expected Results The project will identify key data requirements, deliver a predictive AI model, and develop evidence-based recommendations to support the responsible and scalable implementation of the proposed AI-solution in healthcare and social care settings. Conclusions By combining technical innovation with real-world implementation research, the PAI project seeks to advance the use of AI in care for older persons, support proactive and person-centered interventions, and contribute to more sustainable healthcare systems.
- Open Access
- 18 June 2024
- Published by Universitat Politecnica de Valencia
Challenge-Based Learning in Higher Education: Master’s Degree in Logistics and Productive Operations Management from Mondragón University
Since 2022, Modragon University has implemented Challenge-Based Learning (CBL) in the teaching and learning process of the Master’s in Logistics and Productive Operations Management (MUDOLP) program. This article describes the application of CBL in four companies from different industrial sectors during the second semester of the 2022–2023 academic year. The challenges focused on reducing the variability of industrial processes through the implementation of a continuous improvement process and analysis following the Lean Six Sigma methodology in an environment of operational excellence. The results show that having a partner with experience in the CBL industry is important in increasing the complexity and uncertainty of the task, while also providing students with significant exposure to professional issues that need to be addressed.
- 18 June 2024
- Published by Universitat Politecnica de Valencia
Open AccessChallenge-Based Learning in Higher Education: Master’s Degree in Logistics and Productive Operations Management from Mondragón University
Since 2022, Modragon University has implemented Challenge-Based Learning (CBL) in the teaching and learning process of the Master’s in Logistics and Productive Operations Management (MUDOLP) program. This article describes the application of CBL in four companies from different industrial sectors during the second semester of the 2022–2023 academic year. The challenges focused on reducing the variability of industrial processes through the implementation of a continuous improvement process and analysis following the Lean Six Sigma methodology in an environment of operational excellence. The results show that having a partner with experience in the CBL industry is important in increasing the complexity and uncertainty of the task, while also providing students with significant exposure to professional issues that need to be addressed.
- Open Access
- 1 April 2020
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 20 (2) , 8
Impact Assessment of an Innovative Integrated Care Model for Older Complex Patients with Multimorbidity: The CareWell Project
Objectives: To evaluate the impact in terms of use of health services, clinical outcomes, functional status, and patient´s satisfaction of an integrated care program, the CareWell program, for complex patients with multimorbidity, supported by information and communication technology platforms in six European regions.Data Sources: Primary data were used and the follow-up period ranged between 8 and 12 months.Study design: A quasi-experimental study, targeting chronic patients aged 65 or older, with 2 or more conditions – one of them necessarily being diabetes, congestive heart failure or congestive obstructive pulmonary disease. The intervention group received the integrated care program and the control group received usual care. Generalized mixed regression models were used.Data collection: Data were obtained from individual interviews and electronic clinical records.Principal Findings: Overall, 856 patients were recruited (475 intervention and 381 control). In the intervention group, the number of visits to emergency rooms was significantly lower, and the number of visits to the general practitioners and primary care nurses was higher than in the control group.Conclusion: The CareWell program resulted in improvements in the use of health services, strengthening the role of PC as the cornerstone of care provision for complex patients with multimorbidity.
- 1 April 2020
- Published by Ubiquity Press, Ltd. in International Journal of Integrated Care
- Vol. 20 (2) , 8
Open AccessImpact Assessment of an Innovative Integrated Care Model for Older Complex Patients with Multimorbidity: The CareWell Project
Objectives: To evaluate the impact in terms of use of health services, clinical outcomes, functional status, and patient´s satisfaction of an integrated care program, the CareWell program, for complex patients with multimorbidity, supported by information and communication technology platforms in six European regions.Data Sources: Primary data were used and the follow-up period ranged between 8 and 12 months.Study design: A quasi-experimental study, targeting chronic patients aged 65 or older, with 2 or more conditions – one of them necessarily being diabetes, congestive heart failure or congestive obstructive pulmonary disease. The intervention group received the integrated care program and the control group received usual care. Generalized mixed regression models were used.Data collection: Data were obtained from individual interviews and electronic clinical records.Principal Findings: Overall, 856 patients were recruited (475 intervention and 381 control). In the intervention group, the number of visits to emergency rooms was significantly lower, and the number of visits to the general practitioners and primary care nurses was higher than in the control group.Conclusion: The CareWell program resulted in improvements in the use of health services, strengthening the role of PC as the cornerstone of care provision for complex patients with multimorbidity.
- Open Access
- 1 July 2019
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 15, 2027-2034
Dementia-related neuropsychiatric symptoms: inequalities in pharmacological treatment and institutionalization
Background: Dementia-related neuropsychiatric symptoms (NPS) are the main determinant of family stress and institutionalization of patients. This study aimed to identify inequalities by gender and socioeconomic status in the management of NPS in patients diagnosed with dementia. Methods: An observational study was carried out to study all the cases of dementia in the corporate database of the Basque Health Service (29,864 patients). The prescription of antipsychotics and antidepressants and admission to a nursing home were used to establish the presence of NPS. The socioeconomic status of individuals was classified by a deprivation index. Logistic regressions were used to identify drivers for drug prescriptions and institutionalization. Results: NPS are poorly recorded in the clinical databases (12%). Neuropsychiatric symptoms were severe enough in two thirds of patients with dementia to be treated with psychoactive medication. Institutionalization showed an increase from those who did not receive medication to those who had been prescribed antidepressants (OR: 1.546), antipsychotics (OR: 2.075) or both (OR: 2.741). The resulting inequalities were the increased prescription of antidepressant drugs in women and more nursing-home admissions for women who were the least socioeconomically deprived and men who were the most deprived. Conclusions: In large clinical databases, psychoactive drugs prescriptions can be useful to underscore the considerable burden of dementia-related NPS. Specific tools are needed to monitor social and health care programs targeted to dementia-related NPS from a population perspective. Programs aimed at reducing the family burden of care of dementia patients at home become the key elements in reducing inequalities in these patients’ care. Socioeconomic status is the most important driver of inequality, and gender inequality may simply be hidden within the social environment. Integrated programs boosting the continuity of care are an objective for which compliance could be measured according to the NPS coding in the electronic health record.
- 1 July 2019
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 15, 2027-2034
Open AccessDementia-related neuropsychiatric symptoms: inequalities in pharmacological treatment and institutionalization
Background: Dementia-related neuropsychiatric symptoms (NPS) are the main determinant of family stress and institutionalization of patients. This study aimed to identify inequalities by gender and socioeconomic status in the management of NPS in patients diagnosed with dementia. Methods: An observational study was carried out to study all the cases of dementia in the corporate database of the Basque Health Service (29,864 patients). The prescription of antipsychotics and antidepressants and admission to a nursing home were used to establish the presence of NPS. The socioeconomic status of individuals was classified by a deprivation index. Logistic regressions were used to identify drivers for drug prescriptions and institutionalization. Results: NPS are poorly recorded in the clinical databases (12%). Neuropsychiatric symptoms were severe enough in two thirds of patients with dementia to be treated with psychoactive medication. Institutionalization showed an increase from those who did not receive medication to those who had been prescribed antidepressants (OR: 1.546), antipsychotics (OR: 2.075) or both (OR: 2.741). The resulting inequalities were the increased prescription of antidepressant drugs in women and more nursing-home admissions for women who were the least socioeconomically deprived and men who were the most deprived. Conclusions: In large clinical databases, psychoactive drugs prescriptions can be useful to underscore the considerable burden of dementia-related NPS. Specific tools are needed to monitor social and health care programs targeted to dementia-related NPS from a population perspective. Programs aimed at reducing the family burden of care of dementia patients at home become the key elements in reducing inequalities in these patients’ care. Socioeconomic status is the most important driver of inequality, and gender inequality may simply be hidden within the social environment. Integrated programs boosting the continuity of care are an objective for which compliance could be measured according to the NPS coding in the electronic health record.
- 5 May 2019
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 29 (4) , 681-686
Gender and socioeconomic inequalities in the implementation of the Basque programme for multimorbid patients
Background: The aim of our study was to increase awareness of the relevance of the implemented programmes to inequity of access and inequality of health by analyzing the impact of a patient-centred strategy for multimorbid patients. Methods: This retrospective study compared the 2014 multimorbid patient group (intervention group) with its 2012 analogue (control group), before the Department of Health of the Basque Country launched the strategy for managing disease chronicity. Inequalities in healthcare access were represented by differences in the inclusion of patients in the programme and in contacts with primary care (PC) services by gender and socioeconomic status (measured by deprivation index by census track). Likewise, differences in hospital care represented inequalities in health outcomes. Generalized linear models were used to analyze relationships among variables. A propensity score by a genetic matching approach was used to minimize possible selection bias. Results: At baseline, women had less probability of being eligible for the programme. No clear patterns were seen in resource consumption in PC. The probability of hospitalization was higher for men and increased according to socioeconomic status. The implementation of the programme yielded more contacts with PC services in all groups and a reduction in hospitalizations, especially among men and the most socioeconomically deprived patients. Conclusion: The patient-centred, integrated-care intervention launched by the Department of Health of the Basque Country might have reduced some gender and socioeconomic inequalities in health outcomes, as it avoided more hospitalizations in subgroups that presented with more episodes of decompensation in the reference year.
- 5 May 2019
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 29 (4) , 681-686
Gender and socioeconomic inequalities in the implementation of the Basque programme for multimorbid patients
Background: The aim of our study was to increase awareness of the relevance of the implemented programmes to inequity of access and inequality of health by analyzing the impact of a patient-centred strategy for multimorbid patients. Methods: This retrospective study compared the 2014 multimorbid patient group (intervention group) with its 2012 analogue (control group), before the Department of Health of the Basque Country launched the strategy for managing disease chronicity. Inequalities in healthcare access were represented by differences in the inclusion of patients in the programme and in contacts with primary care (PC) services by gender and socioeconomic status (measured by deprivation index by census track). Likewise, differences in hospital care represented inequalities in health outcomes. Generalized linear models were used to analyze relationships among variables. A propensity score by a genetic matching approach was used to minimize possible selection bias. Results: At baseline, women had less probability of being eligible for the programme. No clear patterns were seen in resource consumption in PC. The probability of hospitalization was higher for men and increased according to socioeconomic status. The implementation of the programme yielded more contacts with PC services in all groups and a reduction in hospitalizations, especially among men and the most socioeconomically deprived patients. Conclusion: The patient-centred, integrated-care intervention launched by the Department of Health of the Basque Country might have reduced some gender and socioeconomic inequalities in health outcomes, as it avoided more hospitalizations in subgroups that presented with more episodes of decompensation in the reference year.
- Open Access
- 1 February 2019
- Published by Elsevier in Atencion Primaria
- Vol. 51 (2) , 80-90
Impacto de la identificación de pacientes en un programa de cuidados paliativos del País Vasco
- 1 February 2019
- Published by Elsevier in Atencion Primaria
- Vol. 51 (2) , 80-90
Open AccessImpacto de la identificación de pacientes en un programa de cuidados paliativos del País Vasco
- 22 November 2018
- Published by Wiley in Health Services Research
- Vol. 54 (2) , 466-473
Impact of stratification on the effectiveness of a comprehensive patient‐centered strategy for multimorbid patients
Objective: The objective of this work was to assess the effectiveness of a population‐level patient‐centered intervention for multimorbid patients based on risk stratification for case finding in 2014 compared with the baseline scenario in 2012.Data Source: Clinical and administrative databases.Study Design: This was an observational cohort study with an intervention group and a historical control group. A propensity score by a genetic matching approach was used to minimize bias. Generalized linear models were used to analyze relationships among variables.Data Collection: We included all eligible patients at the beginning of the year and followed them until death or until the follow‐up period concluded (end of the year). The control group (2012) totaled 3558 patients, and 4225 patients were in the intervention group (2014).Principal Finding: A patient‐centered strategy based on risk stratification for case finding and the implementation of an integrated program based on new professional roles and an extensive infrastructure of information and communication technologies avoided 9 percent (OR: 0.91, CI: 0.86‐0.96) of hospitalizations. However, this effect was not found in nonprioritized groups whose probability of hospitalization increased (OR: 1.19, CI = 1.09‐1.30).Conclusions: In a before‐and‐after analysis using propensity score matching, a comprehensive, patient‐centered, integrated care intervention was associated with a lower risk of hospital admission among prioritized patients, but not among patients who were not prioritized to receive the intervention.
- 22 November 2018
- Published by Wiley in Health Services Research
- Vol. 54 (2) , 466-473
Impact of stratification on the effectiveness of a comprehensive patient‐centered strategy for multimorbid patients
Objective: The objective of this work was to assess the effectiveness of a population‐level patient‐centered intervention for multimorbid patients based on risk stratification for case finding in 2014 compared with the baseline scenario in 2012.Data Source: Clinical and administrative databases.Study Design: This was an observational cohort study with an intervention group and a historical control group. A propensity score by a genetic matching approach was used to minimize bias. Generalized linear models were used to analyze relationships among variables.Data Collection: We included all eligible patients at the beginning of the year and followed them until death or until the follow‐up period concluded (end of the year). The control group (2012) totaled 3558 patients, and 4225 patients were in the intervention group (2014).Principal Finding: A patient‐centered strategy based on risk stratification for case finding and the implementation of an integrated program based on new professional roles and an extensive infrastructure of information and communication technologies avoided 9 percent (OR: 0.91, CI: 0.86‐0.96) of hospitalizations. However, this effect was not found in nonprioritized groups whose probability of hospitalization increased (OR: 1.19, CI = 1.09‐1.30).Conclusions: In a before‐and‐after analysis using propensity score matching, a comprehensive, patient‐centered, integrated care intervention was associated with a lower risk of hospital admission among prioritized patients, but not among patients who were not prioritized to receive the intervention.
- Open Access
- 25 April 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-11
Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model
The Basque Colorectal Cancer Screening Programme began in 2009 and the implementation has been complete since 2013. Faecal immunological testing was used for screening in individuals between 50 and 69 years old. Colorectal Cancer in Basque country is characterized by unusual epidemiological features given that Colorectal Cancer incidence is similar to other European countries while adenoma prevalence is higher. The object of our study was to economically evaluate the programme via cost-effectiveness and budget impact analyses with microsimulation models. We applied the Microsimulation Screening Analysis (MISCAN)-Colon model to predict trends in Colorectal Cancer incidence and mortality and to quantify the short- and long-term effects and costs of the Basque Colorectal Cancer Screening Programme. The model was calibrated to the Basque demographics in 2008 and age-specific Colorectal Cancer incidence data in the Basque Cancer Registry from 2005 to 2008 before the screening begun. The model was also calibrated to the high adenoma prevalence observed for the Basque population in a previously published study. The multi-cohort approach used in the model included all the cohorts in the programme during 30 years of implementation, with lifetime follow-up. Unit costs were obtained from the Basque Health Service and both cost-effectiveness analysis and budget impact analysis were carried out. The goodness-of-fit of the model adaptation to observed programme data was evidence of validation. In the cost-effectiveness analysis, the savings from treatment were larger than the added costs due to screening. Thus, the Basque programme was dominant compared to no screening, as life expectancy increased by 29.3 days per person. The savings in the budget analysis appeared 10 years after the complete implementation of the programme. The average annual budget was €73.4 million from year 2023 onwards. This economic evaluation showed a screening intervention with a major health gain that also produced net savings when a long follow-up was used to capture the late economic benefit. The number of colonoscopies required was high but remain within the capacity of the Basque Health Service. So far in Europe, no other population Colorectal Cancer screening programme has been evaluated by budget impact analysis.
- 25 April 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 1-11
Open AccessCost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model
The Basque Colorectal Cancer Screening Programme began in 2009 and the implementation has been complete since 2013. Faecal immunological testing was used for screening in individuals between 50 and 69 years old. Colorectal Cancer in Basque country is characterized by unusual epidemiological features given that Colorectal Cancer incidence is similar to other European countries while adenoma prevalence is higher. The object of our study was to economically evaluate the programme via cost-effectiveness and budget impact analyses with microsimulation models. We applied the Microsimulation Screening Analysis (MISCAN)-Colon model to predict trends in Colorectal Cancer incidence and mortality and to quantify the short- and long-term effects and costs of the Basque Colorectal Cancer Screening Programme. The model was calibrated to the Basque demographics in 2008 and age-specific Colorectal Cancer incidence data in the Basque Cancer Registry from 2005 to 2008 before the screening begun. The model was also calibrated to the high adenoma prevalence observed for the Basque population in a previously published study. The multi-cohort approach used in the model included all the cohorts in the programme during 30 years of implementation, with lifetime follow-up. Unit costs were obtained from the Basque Health Service and both cost-effectiveness analysis and budget impact analysis were carried out. The goodness-of-fit of the model adaptation to observed programme data was evidence of validation. In the cost-effectiveness analysis, the savings from treatment were larger than the added costs due to screening. Thus, the Basque programme was dominant compared to no screening, as life expectancy increased by 29.3 days per person. The savings in the budget analysis appeared 10 years after the complete implementation of the programme. The average annual budget was €73.4 million from year 2023 onwards. This economic evaluation showed a screening intervention with a major health gain that also produced net savings when a long follow-up was used to capture the late economic benefit. The number of colonoscopies required was high but remain within the capacity of the Basque Health Service. So far in Europe, no other population Colorectal Cancer screening programme has been evaluated by budget impact analysis.
- Open Access
- 1 August 2017
- Published by Springer Nature in BMC Public Health
- Vol. 18 (1) , 1-12
Evaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model
The population-based Basque Colorectal Cancer (CRC) Screening Programme started in 2009 with a biennial immunochemical quantitative test (FIT) biennial and colonoscopy under sedation in positive cases. The population target of 586,700 residents was from 50 to 69 years old and the total coverage was reached at the beginning of 2014. The aim of our study was to determine possible scenarios in terms of incidence, mortality and reduction of Life-years-Lost (L-y-L) in the medium and long term of CRC. Invitations were sent out by the Programme from 2009 to 2014, with combined organizational strategies. Simulation was done by MISCAN-colon (Microsimulation Screening Analysis) over 30 years comparing the results of screening vs no-screening, taking the population-based Cancer Registry into account. Lifetime population and real data from the Programme were used from 2008 to 2012. The model was run differentially for men and women. 924,416 invitations were sent out from 2009 to 2014. The average participation rate was 68.4%, CRC detection rate was 3.4% and the Advanced Adenoma detection rate was 24.0‰, with differences observed in sex and age. Future scenarios showed a higher decrease of incidence (17.2% vs 14.7%), mortality (28.1% vs 22.4%) and L-y-L (22.6% vs 18.4%) in men than women in 2030. The Basque Country CRC Programme results are aligned to its strategy and comparable to other programmes. MISCAN model was found to be a useful tool to predict the benefits of the programme in the future. The effectiveness of the Programme has not been formally established as case control studies are required to determine long term benefits from the screening strategy.
- 1 August 2017
- Published by Springer Nature in BMC Public Health
- Vol. 18 (1) , 1-12
Open AccessEvaluation of the colorectal cancer screening Programme in the Basque Country (Spain) and its effectiveness based on the Miscan-colon model
The population-based Basque Colorectal Cancer (CRC) Screening Programme started in 2009 with a biennial immunochemical quantitative test (FIT) biennial and colonoscopy under sedation in positive cases. The population target of 586,700 residents was from 50 to 69 years old and the total coverage was reached at the beginning of 2014. The aim of our study was to determine possible scenarios in terms of incidence, mortality and reduction of Life-years-Lost (L-y-L) in the medium and long term of CRC. Invitations were sent out by the Programme from 2009 to 2014, with combined organizational strategies. Simulation was done by MISCAN-colon (Microsimulation Screening Analysis) over 30 years comparing the results of screening vs no-screening, taking the population-based Cancer Registry into account. Lifetime population and real data from the Programme were used from 2008 to 2012. The model was run differentially for men and women. 924,416 invitations were sent out from 2009 to 2014. The average participation rate was 68.4%, CRC detection rate was 3.4% and the Advanced Adenoma detection rate was 24.0‰, with differences observed in sex and age. Future scenarios showed a higher decrease of incidence (17.2% vs 14.7%), mortality (28.1% vs 22.4%) and L-y-L (22.6% vs 18.4%) in men than women in 2030. The Basque Country CRC Programme results are aligned to its strategy and comparable to other programmes. MISCAN model was found to be a useful tool to predict the benefits of the programme in the future. The effectiveness of the Programme has not been formally established as case control studies are required to determine long term benefits from the screening strategy.